Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) | MicrobiomeTrials← Back to trialsNCT07260162
Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2027-01Est. Completion: 2029-01
Enrollment target: 24 participants Locations- Institut de Cancérologie de l'Ouest, Saint-Herblain, Loire Atlantique, France
Other microbiome trials you might be interested in
Bladder Urothelial Carcinoma
This study is being done to test the feasibility and accuracy of using an ultrasound-guided core needle biopsy technique…
Rochester, United StatesEst. completion Jul 30, 2030
AdenocarcinomaProstate CancerNeoplasmsCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic Type
Background:
Prostate cancer is the second most common cause of cancer-related death among men in the United States. Ear…
Bethesda, United States
Est. completion Jun 15, 2027
Pancreatic CancerColo-rectal CancerGastric CancerEsophageal CancerBladder CancerOvarian CancerAbdominal Surgery Complications
The goal of this clinical study is to learn whether a prehabilitation program can improve recovery after major abdominal…
Multiple LocationsEst. completion Dec 15, 2029